Trump Signs Executive Order to Speed Psychedelic Drug Research and Funding

President Trump signed an executive order last month that speeds up research and increases federal funding for psychedelic drug therapies. Rep. Lou Correa (D-CA), who has been leading a bipartisan effort to advance such therapies, said the order could help veterans experiencing PTSD or traumatic brain injuries.

He added that it could also benefit those facing other mental health issues. Correa stated that the executive order will expand access to new treatment options that have shown promise in clinical settings for conditions that have not responded well to existing therapies.

The order directs federal agencies to reduce administrative delays in approving studies and to allocate additional resources for research programs.

” — Rep. Supporters argue that streamlined federal processes could accelerate the transition from research trials to approved medical use where data supports safety and efficacy.

Federal funding increases under the order will support expanded clinical trials at approved facilities. Officials have not yet released specific budget figures or implementation timelines for the new directives. The executive order represents a policy shift that builds on prior state-level initiatives and private research efforts exploring psychedelic compounds for mental health treatment.

Further details on agency guidance are expected in coming weeks.